Enanta Pharmaceuticals
ENTA
183 hedge funds and large institutions have $1.19B invested in Enanta Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 54 reducing their positions, and 37 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 54
3% more call options, than puts
Call options by funds: $4.55M | Put options by funds: $4.43M
0.99% more ownership
Funds ownership: 85.76% → 86.75% (+0.99%)
7% less funds holding
Funds holding: 197 → 183 (-14)
16% less capital invested
Capital invested by funds: $1.42B → $1.19B (-$228M)
35% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$47.6M |
| 2 |
Morgan Stanley
New York
|
+$11.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$8.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.59M |
| 5 |
Citigroup
New York
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$19M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.3M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$13.8M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$7.91M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.64M |
ENTA Hedge Fund Activity: Q4 2018 in Review
183 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2018, worth a combined $1.19B — down 16% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ENTA and 24 opened new positions — a net loss of 13 holders — while 54 trimmed existing stakes and 74 added.
The largest buyer was Janus Henderson Group, adding an estimated $47.6M. The largest seller was Invesco, cutting an estimated $19M.
- 183 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2018, down from 197 in Q3 2018.
- Funds reported $1.19B of Enanta Pharmaceuticals stock for Q4 2018, down 16% quarter-over-quarter.
- 24 funds opened new Enanta Pharmaceuticals positions in Q4 2018 and 37 closed out, a net change of -13 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2018 was Janus Henderson Group, an estimated $47.6M added.
- The largest Enanta Pharmaceuticals seller in Q4 2018 was Invesco, an estimated $19M sold.
Based on aggregated 13F filings for Q4 2018.